U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07749664) titled 'DEL-1 and Thromboxane A2 in Diabetic Nephropathy Patients' on July 29.
Brief Summary: Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and a leading cause of chronic kidney disease. Inflammation and platelet activation are believed to play a significant role in its pathogenesis and progression.
Developmental endothelial locus-1 (DEL-1) is an anti-inflammatory protein that regulates leukocyte adhesion and endothelial function, while thromboxane A2 is a marker of platelet activation and contributes to vascular dysfunction.
This study aims to evaluate serum levels of DEL-1 and thromboxane...